Trials / Completed
CompletedNCT03766581
A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel
A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarction in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2,366 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical study is to determine whether the addition of an oral Factor XIa Inhibitor to Aspirin and Clopidogrel is more effective than standard therapy in secondary stroke prevention.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986177 | Oral administration |
| OTHER | Placebo | Oral Administration |
| DRUG | Clopidogrel | Oral administration |
| DRUG | Aspirin | Oral administration |
Timeline
- Start date
- 2019-01-27
- Primary completion
- 2022-03-31
- Completion
- 2022-03-31
- First posted
- 2018-12-06
- Last updated
- 2023-06-12
- Results posted
- 2023-06-12
Locations
424 sites across 29 countries: United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Japan, Mexico, Norway, Poland, Russia, South Korea, Spain, Sweden, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03766581. Inclusion in this directory is not an endorsement.